Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company braces for big regulatory shifts in the weight-loss drug industry.

Future weight-loss offerings will be “primarily composed” of generic weight-loss pills and an older GLP-1 drug called liraglutide. Investors reacted immediately. Shares dropped 22.3% the next day.

KELOWNA, BC / ACCESS Newswire / March 18, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to ...

We have seen very strong M&A activity in the biotech space this year and the trend is expected to continue as big pharmaceutical ...

examined use of the older first-generation GLP-1 RAs such as liraglutide and exenatide, rather than the newer semaglutide and tirzepatide. “The newer ones are much more potent than the first ...

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...